Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.

Details

Serval ID
serval:BIB_A9C9384A62F6
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Journal
Expert Review of Anti-infective Therapy
Author(s)
Manuel O., Perrottet N., Pascual M.
ISSN
1744-8336 (Electronic)
ISSN-L
1478-7210
Publication state
Published
Issued date
2011
Volume
9
Number
11
Pages
955-965
Language
english
Notes
Publication types: Journal Article ; Review
Abstract
Cytomegalovirus (CMV) is generally considered the most significant pathogen to infect patients following organ transplantation. Significant improvements have been achieved in the management of CMV disease over recent years, especially since the introduction of oral drugs such as oral ganciclovir followed by valganciclovir (VGC), a prodrug of ganciclovir with enhanced bioavailability. Several randomized controlled trials have shown that VGC is an efficacious and convenient oral drug to prevent or treat CMV disease in solid-organ transplant recipients. In this article, we discuss the clinical and pharmacological experience with the use of VGC for the management of CMV in solid-organ transplant recipients. Finally, novel strategies to further reduce the incidence of CMV disease after transplantation are also reviewed.
Keywords
Administration, Oral, Antiviral Agents/pharmacokinetics, Antiviral Agents/therapeutic use, Cytokines/biosynthesis, Cytomegalovirus/drug effects, Cytomegalovirus/immunology, Cytomegalovirus Infections/drug therapy, Cytomegalovirus Infections/immunology, Cytomegalovirus Infections/</QualifierName> <QualifierName MajorTopicYN="N">, Drug Dosage Calculations, Ganciclovir/analogs & derivatives, Ganciclovir/pharmacokinetics, Humans, Immunity, Cellular/drug effects, Immunocompromised Host, Organ Transplantation, Practice Guidelines as Topic, Prodrugs/pharmacokinetics, Prodrugs/therapeutic use, Randomized Controlled Trials as Topic, Risk Factors, Transplantation Conditioning/adverse effects, Viral Load/drug effects, Virus Replication/drug effects
Pubmed
Web of science
Create date
17/02/2012 17:00
Last modification date
20/08/2019 15:14
Usage data